How Are ADCs Shaping the Future of Early Breast Cancer Care? Latest Insights and Emerging Strategies
Did you know that, while well established in the metastatic setting, second-generation antibody-drug conjugates are now moving into the early setting? Credit available for this activity expires: 12/10/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/how-are-adcs-shaping-future-early-breast-cancer-care-latest-2025a1000yca?ecd=bdc_podcast_libsyn_mscpedu
--------
31:48
--------
31:48
Pediatric Low-Grade Glioma With BRAF Alterations: Stories, Science, and Strategies
Join the program for an in-depth discussion on low-grade glioma – from burden and diagnosis to therapies. Credit available for this activity expires: 12/10/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/pediatric-low-grade-glioma-braf-alterations-stories-science-2025a1000x3w?ecd=bdc_podcast_libsyn_mscpedu
--------
38:04
--------
38:04
Hot Topics from Berlin 2025: What Experts Say About the Future of Metastatic Breast Cancer Care
Join this program for relevant updates across the advanced and metastatic breast cancer (mBC) spectrum as presented in October 2025. Credit available for this activity expires: 12/8/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/hot-topics-berlin-2025-what-experts-say-about-future-2025a1000x8r?ecd=bdc_podcast_libsyn_mscpedu
--------
30:28
--------
30:28
How Are Oral SERDs Changing the Management of Advanced HR-Positive Breast Cancer?
Where do oral selective estrogen receptor degraders (SERDs) fit in the overall landscape of first- and second-line advanced/metastatic breast cancer? Credit available for this activity expires: 12/04/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/how-are-oral-serds-changing-management-advanced-hr-positive-2025a1000xkg?ecd=bdc_podcast_libsyn_mscpedu
--------
19:55
--------
19:55
Staying Ahead of the First Event: Evaluating the Evidence for Early LDL-C Lowering
Preventing the first ASCVD is critically important. In this activity, we explore the evidence for early and intensive lipid lowering to significantly reduce patient's cardiovascular (CV) risk. Credit available for this activity expires: 12/05/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/staying-ahead-first-event-evaluating-evidence-early-ldl-c-2025a1000xkj?ecd=bdc_podcast_libsyn_mscpedu